Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
6 studies found for:    18309951 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
F-18 Sodium Fluoride in Prostate Cancer
Condition: Prostate Neoplasm
Intervention: Drug: F-18 NaF
2 Not yet recruiting Micro RNAs to Predict Response to Androgen Deprivation Therapy
Condition: Prostate Cancer
Interventions: Drug: Bicalutamide;   Drug: Leuprolide;   Drug: Goserelin;   Drug: Triptorelin;   Drug: Docetaxel
3 Recruiting Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
Condition: Prostatic Neoplasms
Interventions: Drug: Cabozantinib;   Drug: Docetaxel;   Drug: Prednisone
4 Recruiting Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Conditions: Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer;   Stage IV Prostate Cancer
Interventions: Drug: Alisertib;   Drug: Abiraterone acetate;   Drug: Prednisone
5 Recruiting F-choline PET in Early Response Assessment for Castration Resistant Prostatic Cancer
Condition: Castration-resistant Prostate Cancer
Intervention: Device: F-Choline-PET
6 Completed A Safety and Efficacy Study of KX2-391 in Patients With Bone-Metastatic, Castration-Resistant Prostate Cancer Who Have Not Received Prior Chemotherapy
Condition: Bone-Metastatic, Castration-Resistant Prostate Cancer
Intervention: Drug: KX2-391

Indicates status has not been verified in more than two years